A Phase 2 interventional study of Olezarsen and Placebo in Hypertriglyceridemia, Atherosclerotic Cardiovascular Disease and Severe Hypertriglyceridemia, sponsored by Ionis Pharmaceuticals, Inc.. Completed at 24 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-23.
Sponsored by Ionis Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Hypertriglyceridemia by Ionis Pharmaceuticals, Inc. — 1 open to participants now, 2 under way, 1 of them phase 3. Hypertriglyceridemia · Ionis Pharmaceuticals, Inc..
Among the 12 studies in Hypertriglyceridemia by Ionis Pharmaceuticals, Inc., this one is the 5th largest by enrollment, is one of 4 that started in 2022, is one of 5 in phase 2, and was the 8th registered.
324 studies on the registry are indexed under Hypertriglyceridemia; 38 are open to participants now.
Browse Hypertriglyceridemia studies →1 of the 12 studies in Hypertriglyceridemia by Ionis Pharmaceuticals, Inc. is open now, in 2 countries. Recruiting first, the newest first:
Ionis Pharmaceuticals, Inc. · Sites in United States, Canada
Ages 18+
By country, each count listing its studies:
Of the 22 Hypertriglyceridemia studies recruiting now, 9 (41%) set no upper age limit and 12 (55%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 4 started in 2022.
This study's enrollment of 154 is above the median of 66 across 288 interventional studies indexed under Hypertriglyceridemia.
Median enrollment 114 across the 12 interventional studies. Of the 10 that completed or were terminated, 4 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
Ionis Pharmaceuticals, Inc. is the lead sponsor of 118 studies on the registry; 10 are open to participants now.
Of its 49 completed or terminated interventional studies of FDA-regulated products, 22 (45%) have results posted.
2 of the studies in Hypertriglyceridemia by Ionis Pharmaceuticals, Inc. that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05681351Phase 3Ionis Pharmaceuticals, Inc.CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG) | 2027-03 |
| NCT07604974Ionis Pharmaceuticals, Inc.A Study to Assess the Safety, Tolerability and Efficacy of ION775 | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies in Hypertriglyceridemia by Ionis Pharmaceuticals, Inc., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study was to evaluate the effect of olezarsen on percent change in fasting triglyceride (TG) levels compared to placebo at Months 6 and 12 and the proportion of participants who achieve different thresholds in fasting TG. Other objectives were to evaluate the effect of olezarsen on percent change in fasting apolipoprotein C-III (apoC-III), very low-density lipoprotein cholesterol (VLDL-C), remnant cholesterol, non-high-density lipoprotein cholesterol (non-HDL-C), HDL-C, total cholesterol (TC), apolipoprotein B (apoB), low-density lipoprotein cholesterol (LDL-C), and apolipoprotein A-1 (apoA-1).
This was a multi-center, randomized, double-blind, placebo-controlled study in participants with hypertriglyceridemia (triglycerides > 150 milligrams per deciliter [mg/dL]) and established or at increased risk for atherosclerotic cardiovascular disease, and/or with severe hypertriglyceridemia. The study had an up to 8-week screening period, a 53-week treatment period, and a 13-week post-treatment follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Fall into at least 1 of the following groups (a or b):
Exclusion Criteria:
Diabetes with any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received olezarsen-matching placebo, as a single subcutaneous (SC) injection, once every 4 weeks for 53 weeks treatment period.
Drug: Placebo
Participants received olezarsen 50 mg, as a single 0.5 milliliters (mL) SC injection, once every 4 weeks for 53 weeks treatment period.
Drug: Olezarsen
Participants received olezarsen 80 mg, as a single 0.8 mL SC injection, once every 4 weeks for 53 weeks treatment period.
Drug: Olezarsen
SC injection.
Also known as: ISIS 678354, AKCEA-APOCIII-LRx
SC injection.
Percent Change From Baseline in Fasting TG at Month 6
Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 6 was defined as the average of Weeks 25 and 27. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the jump to reference (J2R) approach.
Time frame: Baseline, Month 6
Percent Change From Baseline in Fasting TG at Month 12
Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 12 was defined as the average of Weeks 51 and 53. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.
Time frame: Baseline, Month 12
Percentage of Participants Who Achieved Fasting TG <150 mg/dL (1.69 Millimoles Per Liter [mmol/L]) at Month 6 With Baseline TG <500 mg/dL (5.65 mmol/L)
Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 6 was defined as the average of Weeks 25 and 27. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.
Time frame: Baseline, Month 6
Percentage of Participants Who Achieved Fasting TG <150 mg/dL (1.69 mmol/L) at Month 12 With Baseline TG <500 mg/dL (5.65 mmol/L)
Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 12 was defined as the average of Weeks 51 and 53. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.
Time frame: Baseline, Month 12
Percent Change From Baseline in Fasting Apolipoprotein C-III (ApoC-III) at Month 6
Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 6 was defined as the average of Weeks 25 and 27. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.
Time frame: Baseline, Month 6
Percent Change From Baseline in Fasting ApoC-III at Month 12
Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 12 was defined as the average of Weeks 51 and 53. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.
Time frame: Baseline, Month 12
Percent Change From Baseline in Fasting Very Low-density Lipoprotein Cholesterol (VLDL-C) at Month 6
Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 6 was defined as the average of Weeks 25 and 27. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.
Time frame: Baseline, Month 6
Percent Change From Baseline in VLDL-C at Month 12
Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 12 was defined as the average of Weeks 51 and 53. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.
Time frame: Baseline, Month 12
Percent Change From Baseline in Fasting Non-high-density Lipoprotein Cholesterol (Non-HDL-C) at Month 6
Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 6 was defined as the average of Weeks 25 and 27. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.
Time frame: Baseline, Month 6
Percent Change From Baseline in Fasting Non-HDL-C at Month 12
Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 12 was defined as the average of Weeks 51 and 53. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.
Time frame: Baseline, Month 12
Percent Change From Baseline in Fasting High-density Lipoprotein Cholesterol (HDL-C) at Month 6
Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 6 was defined as the average of Weeks 25 and 27. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.
Time frame: Baseline, Month 6
Percent Change From Baseline in Fasting HDL-C at Month 12
Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 12 was defined as the average of Weeks 51 and 53. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.
Time frame: Baseline, Month 12
Percent Change From Baseline Fasting Remnant Cholesterol (Remnant-C) at Month 6
Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 6 was defined as the average of Weeks 25 and 27. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.
Time frame: Baseline, Month 6
Percent Change From Baseline in Fasting Remnant-C at Month 12
Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 12 was defined as the average of Weeks 51 and 53. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.
Time frame: Baseline, Month 12
Percent Change From Baseline in Fasting Apolipoprotein B (ApoB) at Month 6
Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 6 was defined as the average of Weeks 25 and 27. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.
Time frame: Baseline, Month 6
Percent Change From Baseline in Fasting ApoB at Month 12
Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 12 was defined as the average of Weeks 51 and 53. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.
Time frame: Baseline, Month 12
Percent Change From Baseline in Fasting Apolipoprotein A-1 (ApoA-1) at Month 6
Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 6 was defined as the average of Weeks 25 and 27. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.
Time frame: Baseline, Month 6
Percent Change From Baseline in Fasting ApoA-1 at Month 12
Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 12 was defined as the average of Weeks 51 and 53. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.
Time frame: Baseline, Month 12
Percent Change From Baseline in Fasting Low-density Lipoprotein Cholesterol (LDL-C) at Month 6
Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 6 was defined as the average of Weeks 25 and 27. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.
Time frame: Baseline, Month 6
Percent Change From Baseline in Fasting LDL-C at Month 12
Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 12 was defined as the average of Weeks 51 and 53. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.
Time frame: Baseline, Month 12
Percent Change From Baseline in Fasting Total Cholesterol (Total-C) at Month 6
Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 6 was defined as the average of Weeks 25 and 27. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.
Time frame: Baseline, Month 6
Percent Change From Baseline in Fasting Total-C at Month 12
Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 12 was defined as the average of Weeks 51 and 53. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.
Time frame: Baseline, Month 12
Percentage of Participants Who Achieved Fasting TG <500 mg/dL (5.65 mmol/L) With Baseline TG ≥500 mg/dL at Month 6
Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 6 was defined as the average of Weeks 25 and 27. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.
Time frame: Baseline, Month 6
Percentage of Participants Who Achieved Fasting TG <500 mg/dL (5.65 mmol/L) With Baseline TG ≥500 mg/dL at Month 12
Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 12 was defined as the average of Weeks 51 and 53. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.
Time frame: Baseline, Month 12
Number of Participants With Adjudicated Acute Pancreatitis Events
All adverse events (AEs) and serious adverse events (SAEs) that consistently occurred during the study with an event of acute pancreatitis were adjudicated by a blinded, independent committee according to the Atlanta classification of acute pancreatitis as outlined in the Acute Pancreatitis Adjudication Committee (PAC) Charter. These events were categorized as 1) documented pancreatitis, 2) probable pancreatitis, 3) possible pancreatitis, 4) unable to adjudicate and 5) no diagnosis of acute pancreatitis. Number of participants with adjudicated acute pancreatitis events were reported.
Time frame: Up to 12 months
Number of Participants With Adjudicated Acute Pancreatitis Events (≥2 Events in 5 Years Prior to Enrollment)
The adjudicated acute pancreatitis event rates were compared between pooled olezarsen treatment and placebo group using a negative binomial regression model or Poisson regression model with the treatment group and natural log transformed baseline fasting TG as the factors, and number of adjudicated acute pancreatitis events in 5 years prior to enrollment as a covariate. The logarithm of time in year that each participant observed during the treatment period were used as an offset variable. Number of participants with adjudicated acute pancreatitis events with ≥2 events in 5 years prior to enrollment were reported.
Time frame: Up to 12 months
Participants took part at 28 clinical sites including 21 sites in the United States (US) and 7 sites in Canada from 01 June 2022 to 17 January 2023.
| Milestone | Placebo | Olezarsen 50 mg | Olezarsen 80 mg |
|---|---|---|---|
| Started | 39 | 58 | 57 |
| Completed | 38 | 51 | 52 |
| Not completed | 1 | 7 | 5 |
Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 6 was defined as the average of Weeks 25 and 27. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the jump to reference (J2R) approach.
| Percent Change | Placebo | Olezarsen 50 mg | Olezarsen 80 mg |
|---|---|---|---|
| Percent Change From Baseline in Fasting TG at Month 6 | -7.77 (-15.34 to -0.21) | -57.05 (-63.19 to -50.92) | -60.92 (-67.11 to -54.73) |
Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 12 was defined as the average of Weeks 51 and 53. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.
| percent change | Placebo | Olezarsen 50 mg | Olezarsen 80 mg |
|---|---|---|---|
| Percent Change From Baseline in Fasting TG at Month 12 | -5.59 (-13.09 to 1.90) | -51.67 (-57.74 to -45.60) | -60.39 (-66.51 to -54.27) |
Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 6 was defined as the average of Weeks 25 and 27. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.
| percentage of participants | Placebo | Olezarsen 50 mg | Olezarsen 80 mg |
|---|---|---|---|
| Percentage of Participants Who Achieved Fasting TG <150 mg/dL (1.69 Millimoles Per Liter [mmol/L]) at Month 6 With Baseline TG <500 mg/dL (5.65 mmol/L) | 11.4 | 79.2 | 84.0 |
Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 12 was defined as the average of Weeks 51 and 53. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.
| percentage of participants | Placebo | Olezarsen 50 mg | Olezarsen 80 mg |
|---|---|---|---|
| Percentage of Participants Who Achieved Fasting TG <150 mg/dL (1.69 mmol/L) at Month 12 With Baseline TG <500 mg/dL (5.65 mmol/L) | 5.7 | 69.8 | 82.0 |
Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 6 was defined as the average of Weeks 25 and 27. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.
| percent change | Placebo | Olezarsen 50 mg | Olezarsen 80 mg |
|---|---|---|---|
| Percent Change From Baseline in Fasting Apolipoprotein C-III (ApoC-III) at Month 6 | -5.47 (-16.46 to 5.51) | -69.63 (-79.56 to -59.71) | -78.72 (-87.79 to -69.65) |
Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 12 was defined as the average of Weeks 51 and 53. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.
| percent change | Placebo | Olezarsen 50 mg | Olezarsen 80 mg |
|---|---|---|---|
| Percent Change From Baseline in Fasting ApoC-III at Month 12 | -12.40 (-24.02 to -0.77) | -69.09 (-79.42 to -58.76) | -83.78 (-93.22 to -74.34) |
Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 6 was defined as the average of Weeks 25 and 27. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.
| percent change | Placebo | Olezarsen 50 mg | Olezarsen 80 mg |
|---|---|---|---|
| Percent Change From Baseline in Fasting Very Low-density Lipoprotein Cholesterol (VLDL-C) at Month 6 | -9.74 (-20.65 to 1.17) | -55.93 (-65.65 to -46.22) | -59.46 (-68.79 to -50.13) |
Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 12 was defined as the average of Weeks 51 and 53. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.
| percent change | Placebo | Olezarsen 50 mg | Olezarsen 80 mg |
|---|---|---|---|
| Percent Change From Baseline in VLDL-C at Month 12 | -14.90 (-23.97 to -5.82) | -58.00 (-66.11 to -49.88) | -66.67 (-74.47 to -58.87) |
Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 6 was defined as the average of Weeks 25 and 27. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.
| percent change | Placebo | Olezarsen 50 mg | Olezarsen 80 mg |
|---|---|---|---|
| Percent Change From Baseline in Fasting Non-high-density Lipoprotein Cholesterol (Non-HDL-C) at Month 6 | 3.28 (-7.04 to 13.61) | -22.11 (-31.33 to -12.89) | -19.79 (-28.72 to -10.85) |
Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 12 was defined as the average of Weeks 51 and 53. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.
| percent change | Placebo | Olezarsen 50 mg | Olezarsen 80 mg |
|---|---|---|---|
| Percent Change From Baseline in Fasting Non-HDL-C at Month 12 | -2.55 (-11.91 to 6.81) | -20.00 (-28.23 to -11.76) | -26.57 (-34.59 to -18.55) |
Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 6 was defined as the average of Weeks 25 and 27. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.
| percent change | Placebo | Olezarsen 50 mg | Olezarsen 80 mg |
|---|---|---|---|
| Percent Change From Baseline in Fasting High-density Lipoprotein Cholesterol (HDL-C) at Month 6 | 8.38 (-3.70 to 20.46) | 48.02 (37.00 to 59.04) | 48.01 (37.18 to 58.83) |
Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 12 was defined as the average of Weeks 51 and 53. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.
| percent change | Placebo | Olezarsen 50 mg | Olezarsen 80 mg |
|---|---|---|---|
| Percent Change From Baseline in Fasting HDL-C at Month 12 | 10.53 (-1.87 to 22.94) | 54.20 (42.94 to 65.47) | 57.43 (46.32 to 68.53) |
Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 6 was defined as the average of Weeks 25 and 27. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.
| percent change | Placebo | Olezarsen 50 mg | Olezarsen 80 mg |
|---|---|---|---|
| Percent Change From Baseline Fasting Remnant Cholesterol (Remnant-C) at Month 6 | -9.46 (-20.39 to 1.47) | -55.98 (-65.73 to -46.23) | -59.59 (-68.96 to -50.22) |
Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 12 was defined as the average of Weeks 51 and 53. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.
| percent change | Placebo | Olezarsen 50 mg | Olezarsen 80 mg |
|---|---|---|---|
| Percent Change From Baseline in Fasting Remnant-C at Month 12 | -14.83 (-23.85 to -5.82) | -58.17 (-66.20 to -50.13) | -66.90 (-74.63 to -59.17) |
Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 6 was defined as the average of Weeks 25 and 27. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.
| percent change | Placebo | Olezarsen 50 mg | Olezarsen 80 mg |
|---|---|---|---|
| Percent Change From Baseline in Fasting Apolipoprotein B (ApoB) at Month 6 | 6.82 (-1.44 to 15.07) | -11.42 (-18.80 to -4.03) | -11.67 (-18.80 to -4.53) |
Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 12 was defined as the average of Weeks 51 and 53. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.
| percent change | Placebo | Olezarsen 50 mg | Olezarsen 80 mg |
|---|---|---|---|
| Percent Change From Baseline in Fasting ApoB at Month 12 | 0.68 (-7.09 to 8.44) | -11.67 (-18.45 to -4.90) | -18.53 (-25.12 to -11.93) |
Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 6 was defined as the average of Weeks 25 and 27. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.
| percent change | Placebo | Olezarsen 50 mg | Olezarsen 80 mg |
|---|---|---|---|
| Percent Change From Baseline in Fasting Apolipoprotein A-1 (ApoA-1) at Month 6 | 2.84 (-2.19 to 7.87) | 17.37 (12.82 to 21.93) | 14.91 (10.49 to 19.32) |
Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 12 was defined as the average of Weeks 51 and 53. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.
| percent change | Placebo | Olezarsen 50 mg | Olezarsen 80 mg |
|---|---|---|---|
| Percent Change From Baseline in Fasting ApoA-1 at Month 12 | 0.81 (-4.11 to 5.72) | 16.37 (11.97 to 20.78) | 15.46 (11.15 to 19.76) |
Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 6 was defined as the average of Weeks 25 and 27. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.
| percent change | Placebo | Olezarsen 50 mg | Olezarsen 80 mg |
|---|---|---|---|
| Percent Change From Baseline in Fasting Low-density Lipoprotein Cholesterol (LDL-C) at Month 6 | 40.46 (25.11 to 55.80) | 30.61 (16.44 to 44.77) | 32.74 (19.35 to 46.14) |
Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 12 was defined as the average of Weeks 51 and 53. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.
| percent change | Placebo | Olezarsen 50 mg | Olezarsen 80 mg |
|---|---|---|---|
| Percent Change From Baseline in Fasting LDL-C at Month 12 | 35.08 (21.09 to 49.08) | 32.99 (20.52 to 45.46) | 27.27 (15.28 to 39.26) |
Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 6 was defined as the average of Weeks 25 and 27. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.
| percent change | Placebo | Olezarsen 50 mg | Olezarsen 80 mg |
|---|---|---|---|
| Percent Change From Baseline in Fasting Total Cholesterol (Total-C) at Month 6 | 2.99 (-4.94 to 10.92) | -6.78 (-13.86 to 0.30) | -6.48 (-13.31 to 0.35) |
Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 12 was defined as the average of Weeks 51 and 53. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.
| percent change | Placebo | Olezarsen 50 mg | Olezarsen 80 mg |
|---|---|---|---|
| Percent Change From Baseline in Fasting Total-C at Month 12 | -2.15 (-9.25 to 4.95) | -6.08 (-12.35 to 0.18) | -10.80 (-16.87 to -4.72) |
Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 6 was defined as the average of Weeks 25 and 27. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.
| percentage of participants | Placebo | Olezarsen 50 mg | Olezarsen 80 mg |
|---|---|---|---|
| Percentage of Participants Who Achieved Fasting TG <500 mg/dL (5.65 mmol/L) With Baseline TG ≥500 mg/dL at Month 6 | 75.0 | 80.0 | 100.0 |
Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 12 was defined as the average of Weeks 51 and 53. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.
| percentage of participants | Placebo | Olezarsen 50 mg | Olezarsen 80 mg |
|---|---|---|---|
| Percentage of Participants Who Achieved Fasting TG <500 mg/dL (5.65 mmol/L) With Baseline TG ≥500 mg/dL at Month 12 | 75.0 | 100.0 | 100.0 |
All adverse events (AEs) and serious adverse events (SAEs) that consistently occurred during the study with an event of acute pancreatitis were adjudicated by a blinded, independent committee according to the Atlanta classification of acute pancreatitis as outlined in the Acute Pancreatitis Adjudication Committee (PAC) Charter. These events were categorized as 1) documented pancreatitis, 2) probable pancreatitis, 3) possible pancreatitis, 4) unable to adjudicate and 5) no diagnosis of acute pancreatitis. Number of participants with adjudicated acute pancreatitis events were reported.
| Participants | Placebo | Olezarsen 50 mg | Olezarsen 80 mg |
|---|---|---|---|
| Number of Participants With Adjudicated Acute Pancreatitis Events | 0 | 0 | 0 |
The adjudicated acute pancreatitis event rates were compared between pooled olezarsen treatment and placebo group using a negative binomial regression model or Poisson regression model with the treatment group and natural log transformed baseline fasting TG as the factors, and number of adjudicated acute pancreatitis events in 5 years prior to enrollment as a covariate. The logarithm of time in year that each participant observed during the treatment period were used as an offset variable. Number of participants with adjudicated acute pancreatitis events with ≥2 events in 5 years prior to enrollment were reported.
| Participants | Placebo | Olezarsen 50 mg | Olezarsen 80 mg |
|---|---|---|---|
| Number of Participants With Adjudicated Acute Pancreatitis Events (≥2 Events in 5 Years Prior to Enrollment) | 0 | 0 | 0 |
Collected over Up to 15 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/39 (0%) | 2/39 (5.1%) | 22/39 (56.4%) |
| Olezarsen 50 mg | 1/58 (1.7%) | 6/58 (10.3%) | 32/58 (55.2%) |
| Olezarsen 80 mg | 0/57 (0%) | 8/57 (14%) | 24/57 (42.1%) |
| Event | Placebo | Olezarsen 50 mg | Olezarsen 80 mg |
|---|---|---|---|
| Tibia fractureInjury, poisoning and procedural complications | 1/39 | 0/58 | 1/57 |
| Head injuryInjury, poisoning and procedural complications | 1/39 | 0/58 | 0/57 |
| Ligament sprainInjury, poisoning and procedural complications | 1/39 | 0/58 | 0/57 |
| Endometrial cancer stage INeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/39 | 0/58 | 0/57 |
| SyncopeNervous system disorders | 1/39 | 0/58 | 0/57 |
| Angina pectorisCardiac disorders | 0/39 | 0/58 | 1/57 |
| TachycardiaCardiac disorders | 0/39 | 0/58 | 1/57 |
| Small intestinal obstructionGastrointestinal disorders | 0/39 | 0/58 | 1/57 |
| Drug withdrawal syndromeGeneral disorders | 0/39 | 0/58 | 1/57 |
| SepsisInfections and infestations | 0/39 | 1/58 | 1/57 |
| Event | Placebo | Olezarsen 50 mg | Olezarsen 80 mg |
|---|---|---|---|
| Urinary tract infectionInfections and infestations | 6/39 | 6/58 | 3/57 |
| Injection site erythemaGeneral disorders | 0/39 | 8/58 | 2/57 |
| FatigueGeneral disorders | 1/39 | 6/58 | 1/57 |
| SinusitisInfections and infestations | 4/39 | 1/58 | 1/57 |
| COVID-19Infections and infestations | 2/39 | 5/58 | 4/57 |
| Back painMusculoskeletal and connective tissue disorders | 1/39 | 5/58 | 1/57 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/39 | 5/58 | 0/57 |
| BronchitisInfections and infestations | 3/39 | 3/58 | 0/57 |
| Glomerular filtration rate decreasedInvestigations | 3/39 | 1/58 | 0/57 |
| Diabetes mellitusMetabolism and nutrition disorders | 1/39 | 4/58 | 4/57 |
Full analysis set (FAS) included all participants who were randomized and received any amount of study drug (olezarsen or placebo) and who have at least one post-baseline TG assessment.
| Age, Continuous(years) | Placebo | Olezarsen 50 mg | Olezarsen 80 mg | Total |
|---|---|---|---|---|
| Mean | 63.3 ± 9.52 | 62.3 ± 10.15 | 60.4 ± 10.77 | 61.8 ± 10.24 |
| Sex: Female, Male(Participants) | Placebo | Olezarsen 50 mg | Olezarsen 80 mg | Total |
|---|---|---|---|---|
| Female | 24 | 24 | 17 | 65 |
| Male | 15 | 34 | 40 | 89 |
| Race (NIH/OMB)(Participants) | Placebo | Olezarsen 50 mg | Olezarsen 80 mg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 5 | 3 | 5 | 13 |
| White | 34 | 54 | 52 | 140 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Fasting Triglycerides (TG)(milligrams/deciliter (mg/dL)) | Placebo | Olezarsen 50 mg | Olezarsen 80 mg | Total |
|---|---|---|---|---|
| Mean | 302.1 ± 201.91 | 292.1 ± 183.01 | 315.1 ± 221.63 | 303.2 ± 201.7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2022 to primary completion in Mar 2023, 10 months.
Results were first posted in Apr 2026, 3 years 1 month after primary completion. A results delay was requested in Feb 2024.
Of 23 phase 2 interventional studies under Hypertriglyceridemia, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 10 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olezarsen